5258 Nucleic Acids Research, 2010, Vol. 38, No. 15 SUPPLEMENTARY DATA Supplementary Data are available at NAR Online. FUNDING National Institutes of Health (NIGMS 77253); Robert A. Welch Foundation (I-1244); Fonds que´ be´ cois de la recherche sur la nature et les technologies (postdoctoral fellowship to J.K.W.); Alnylam Pharmaceuticals. Funding for open access charge: National Institutes of Health. Conﬂict of interest statement. None declared. REFERENCES 1. de Fougerolles,A., Vornlocher,H.-P., Maraganore,J. and Lieberman,J. (2007) Interfering with disease: a progress report on siRNA-based therapeutics. Nat. Rev. Drug Discov., 6, 443–453. 2. Manoharan,M. (2004) RNA interference and chemically modiﬁed small interfering RNAs. Curr. Opin. Chem. Biol., 8, 570–579. 3. Corey,D.R. (2007) Chemical modiﬁcation: the key to clinical application of RNA interference? J. Clin. Invest., 117, 3615–3622. 4. Watts,J.K., Deleavey,G.F. and Damha,M.J. (2008) Chemically modiﬁed siRNA: tools and applications. Drug Discov. Today, 13, 842–855. 5. Jackson,A.L., Burchard,J., Leake,D., Reynolds,A., Schelter,J., Guo,J., Johnson,J.M., Lim,L., Karpilow,J., Nichols,K. et al. (2006) Position-speciﬁc chemical modiﬁcation of siRNAs reduces ‘‘oﬀ-target’’ transcript silencing. RNA, 12, 1197–1205. 6. Ui-Tei,K., Naito,Y., Zenno,S., Nishi,K., Yamato,K., Takahashi,F., Juni,A. and Saigo,K. (2008) Functional dissection of siRNA sequence by systematic DNA substitution: modiﬁed siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with signiﬁcantly reduced oﬀ-target eﬀect. Nucleic Acids Res., 36, 2136–2151. 7. Judge,A. and MacLachlan,I. (2008) Overcoming the innate immune response to small interfering RNA. Hum. Gene Ther., 19, 111–124. 8. Robbins,M., Judge,A. and MacLachlan,I. (2009) siRNA and innate immunity. Oligonucleotides, 19, 89–102. 9. Bramsen,J.B., Laursen,M.B., Damgaard,C.K., Lena,S.W., Ravindra Babu,B., Wengel,J. and Kjems,J. (2007) Improved silencing properties using small internally segmented interfering RNAs. Nucleic Acids Res., 35, 5886–5897. 10. Chen,P.Y., Weinmann,L., Gaidatzis,D., Pei,Y., Zavolan,M., Tuschl,T. and Meister,G. (2008) Strand-speciﬁc 50-O-methylation of siRNA duplexes controls guide strand selection and targeting speciﬁcity. RNA, 14, 263–274. 11. Parrish,S., Fleenor,J., Xu,S., Mello,C. and Fire,A. (2000) Functional anatomy of a dsRNA trigger: diﬀerential requirement for the two trigger strands in RNA interference. Mol. Cell, 6, 1077–1087. 12. Martinez,J., Patkaniowska,A., Urlaub,H., Luhrmann,R. and Tuschl,T. (2002) Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell, 110, 563–574. 13. Schwarz,D.S., Hutv a´gner,G., Haley,B. and Zamore,P.D. (2002) Evidence that siRNAs function as guides, not primers, in the Drosophila and human RNAi pathways. Mol. Cell, 10, 537–548. 14. Chiu,Y.-L. and Rana,T.M. (2002) RNAi in human cells: basic structural and functional features of small interfering RNA. Mol. Cell, 10, 549–561. 15. Rand,T.A., Petersen,S., Du,F. and Wang,X. (2005) Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation. Cell, 123, 621–629. 16. Leuschner,P.J.F., Ameres,S.L., Kueng,S. and Martinez,J. (2006) Cleavage of the siRNA passenger strand during RISC assembly in human cells. EMBO Rep., 7, 314–320. 17. De Paula,D., Bentley,M.V.L.B. and Mahato,R.I. (2007) Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. RNA, 13, 431–456. 18. Soutschek,J., Akinc,A., Bramlage,B., Charisse,K., Constien,R., Donoghue,M., Elbashir,S., Geick,A., Hadwiger,P., Harborth,J. et al. (2004) Therapeutic silencing of an endogenous gene by systemic administration of modiﬁed siRNAs. Nature, 432, 173–178. 19. Morris,K.V., Chan,S.W.L., Jacobsen,S.E. and Looney,D.J. (2004) Small interfering RNA-induced transcriptional gene silencing in human cells. Science, 305, 1289–1292. 20. Janowski,B.A., Huﬀman,K.E., Schwartz,J.C., Ram,R., Hardy,D., Shames,D.S., Minna,J.D. and Corey,D.R. (2005) Inhibiting gene expression at transcription start sites in chromosomal DNA with antigene RNAs. Nat. Chem. Biol., 1, 216–222. 21. Janowski,B.A., Hu,J. and Corey,D.R. (2006) Silencing gene expression by targeting chromosomal DNA with antigene peptide nucleic acids and duplex RNAs. Nat. Protocols, 1, 436–443. 22. Li,L.-C., Okino,S.T., Zhao,H., Pookot,D., Place,R.F., Urakami,S., Enokida,H. and Dahiya,R. (2006) Small dsRNAs induce transcriptional activation in human cells. Proc. Natl Acad. Sci. USA, 103, 17337–17342. 23. Janowski,B.A., Younger,S.T., Hardy,D.B., Ram,R., Huﬀman,K.E. and Corey,D.R. (2007) Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nat. Chem. Biol., 3, 166–173. 24. Morris,K.V., Santoso,S., Turner,A.M., Pastori,C. and Hawkins,P.G. (2008) Bidirectional transcription directs both transcriptional gene activation and suppression in human cells. PLoS Genet., 4, e1000258. 25. Janowski,B.A., Huﬀman,K.E., Schwartz,J.C., Ram,R., Nordsell,R., Shames,D.S., Minna,J.D. and Corey,D.R. (2006) Involvement of AGO1 and AGO2 in mammalian transcriptional silencing. Nat. Struct. Mol. Biol., 13, 787–792. 26. Kim,D.H., Villeneuve,L.M., Morris,K.V. and Rossi,J.J. (2006) Argonaute-1 directs siRNA-mediated transcriptional gene silencing in human cells. Nat. Struct. Mol. Biol., 13, 793–797. 27. Han,J., Kim,D. and Morris,K.V. (2007) Promoter-associated RNA is required for RNA-directed transcriptional gene silencing in human cells. Proc. Natl Acad. Sci. USA, 104, 12422–12427. 28. Schwartz,J.C., Younger,S.T., Nguyen,N.B., Hardy,D.B., Monia,B.P., Corey,D.R. and Janowski,B.A. (2008) Antisense transcripts are targets for activating small RNAs. Nat. Struct. Mol. Biol., 15, 842–848. 29. Hardy,D.B., Janowski,B.A., Corey,D.R. and Mendelson,C.R. (2006) Progesterone receptor plays a major antiinﬂammatory role in human myometrial cells by antagonism of nuclear factor-kB activation of cyclooxygenase 2 expression. Mol. Endocrinol., 20, 2724–2733. 30. Elbashir,S.M., Harborth,J., Lendeckel,W., Yalcin,A., Weber,K. and Tuschl,T. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 411, 494–498. 31. Kawasaki,A.M., Casper,M.D., Freier,S.M., Lesnik,E.A., Zounes,M.C., Cummins,L.L., Gonzalez,C. and Cook,P.D. (1993) Uniformly modiﬁed 20-deoxy-20-ﬂuoro-phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high aﬃnity and speciﬁcity for RNA targets. J. Med. Chem., 36, 831–841. 32. Layzer,J.M., McCaﬀrey,A.P., Tanner,A.K., Huang,Z.A.N., Kay,M.A. and Sullenger,B.A. (2004) In vivo activity of nuclease-resistant siRNAs. RNA, 10, 766–771. 33. Morrissey,D.V., Blanchard,K., Shaw,L., Jensen,K., Lockridge,J.A., Dickinson,B., McSwiggen,J.A., Vargeese,C., Bowman,K., Shaﬀer,C.S. et al. (2005) Activity of stabilized short interfering RNA in a mouse model of hepatitis B virus replication. Hepatology, 41, 1349–1356. 34. Chiu,Y.L. and Rana,T.M. (2003) siRNA function in RNAi: a chemical modiﬁcation analysis. RNA, 9, 1034–1048. 35. Braasch,D.A., Jensen,S., Liu,Y., Kaur,K., Arar,K., White,M.A. and Corey,D.R. (2003) RNA interference in mammalian cells by chemically-modiﬁed RNA. Biochemistry, 42, 7967–7975. 36. Harborth,J., Elbashir,S.M., Vandenburgh,K., Manninga,H., Scaringe,S.A., Weber,K. and Tuschl,T. (2003) Sequence, chemical, and structural variation of small interfering RNAs and short